Coloplast needs financial tailwinds to reach upper end of forecast
In its current strategy, Strive25, Coloplast expects organic growth in the 8-10% range and an operating margin, EBIT, before special items of more than 30% after 2024/25.
by MARKETWIRE
Coloplast has decided to maintain its long-term forecast under the Strive25 strategy but meeting the upper end of the company’s organic growth expectations will require headwinds in China and within the Urology division to subside, CFO Anders Lonning-Skovgaard said at the company’s capital markets day.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
